Abstract: A consumable container for filling with a fluid in a bioprocessing process. The container comprises one or more sealable, removable portions, such that one or more samples of the fluid may be taken by sealing and removing one or more of said portions.

Abstract: A consumable container for filling with a fluid in a bioprocessing process. The container comprises one or more sealable, removable portions, such that one or more samples of the fluid may be taken by sealing and removing one or more of said portions.

Abstract: A linear peristaltic pump (200) for a bioprocessing system comprises: at least one pair of jaws formed by a first jaw (201) and a second jaw (202), the first jaw (201) being moveable relative to the second jaw (202) such that the pair of jaws can be moved between an open configuration in which the jaws are spaced apart for receiving a flexible tube (155) therebetween and a closed configuration in which the jaws are brought together so as to retain the tube therebetween; an actuator mechanism configured to control movement of the first jaw relative to the second jaw; and means (220a-220m) for effecting a peristaltic pumping action on a fluid contained within the tube (155) when the tube is retained between the pair of jaws in the closed configuration.

Abstract: An automated apparatus for joining a first tube to another such tube whereby to form a fluidic path therethrough, comprising: means for engaging the tube and moving it into one or more positions to be manipulated; means for clamping a portion of the tube whereby to form a pinched portion of the tube such that the tube is fluidly sealed upstream of the pinched portion; means for removing an end section of the tube downstream of the pinched portion such that a new end of the tube is thereby formed within the pinched portion that has not previously contacted another such tube; and means for joining the pinched portion at the new end of the tube with a corresponding pinched portion of another such tube; wherein the apparatus is configured as an end effector for a robotic device.

Abstract: A bioprocessing system comprising a series of processing stations for performing operations for bioprocessing is disclosed. The bioprocessing system includes an automated system comprising means for manipulating a fluid connection between a first container and a separable second container whereby to create an aseptic connection that enables a controlled transfer of fluid or cell material between the first container and the second container, wherein the means for manipulating a fluid connection is configured to create an aseptic connection that can be disconnected after the transfer of fluid or cell material is complete to enable a further such fluid connection to be manipulated between the first container and a separable third container, and means for controlling an automated sequence of operation of the processing stations.

Abstract: A consumable container for filling with a fluid in a bioprocessing process. The container comprises one or more sealable, removable portions, such that one or more samples of the fluid may be taken by sealing and removing one or more of said portions.

Abstract: A consumable container for filling with a fluid in a bioprocessing process. The container comprises one or more sealable, removable portions, such that one or more samples of the fluid may be taken by sealing and removing one or more of said portions.

Abstract: A consumable container for filling with a fluid in a bioprocessing process. The container comprises one or more sealable, removable portions, such that one or more samples of the fluid may be taken by sealing and removing one or more of said portions.

Abstract: A wheeled standalone platform implement having at least two or more swivel casters, each swivel caster is into engagement at a proximate lower base portion of said platform, wherein said at least two or more swivel casters are configured to allow a movement of said platform in any direction. A slot section disposed at a mid-portion of said platform is configured to allow a toe plate of a handcart or a dolly to engage said platform. A locking mechanism is disposed to prevent the wheeled standalone platform from sliding off the toe plate during use.

Abstract: The present invention relates to the identification of a gene, now designated negevin (ngvn), that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human NGVN protein disclosed herein is 731 amino acids in length and is coded for by a gene spanning 17 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Abstract: The present invention relates to the identification of a gene, now designated negevin (ngvn), that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human NGVN protein disclosed herein is 731 amino acids in length and is coded for by a gene spanning 17 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Abstract: The present invention relates to the identification of a gene, now designated negevin (ngvn), that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human NGVN protein disclosed herein is 731 amino acids in length and is coded for by a gene spanning 17 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Abstract: The present invention relates to the designation of ADP-ribosylation factor-like 6 as the BBS3 gene, that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Abstract: Methods and compositions for diagnosing and treating glaucoma are disclosed.

Abstract: The present invention relates to the identification of a gene, now designated negevin (ngvn), that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human NGVN protein disclosed herein is 731 amino acids in length and is coded for by a gene spanning 17 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Abstract: The present invention relates to the designation of ADP-ribosylation factor-like 6 as the BBS3 gene, that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Abstract: The present invention relates to the identification of a gene, mutated at the most common locus now designated BBS1, that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypogonadism, mental retardation, renal cancer and other renal abnormalities, retinopathy and polydactyly or limb deformities. The human BBS1 protein disclosed herein is composed of 17 exons and spans approximately 23 kb. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Abstract: The present invention relates to the identification of a gene, now designated negevin (ngvn), that is involved in the genetic disease Bardet Biedl Syndrome (BBS), which is characterized by such diverse symptoms as obesity, diabetes, hypertension, mental retardation, renal cancer and other abnormalities, retinopathy and hypogonadism. The human NGVN protein disclosed herein is 731 amino acids in length and is coded for by a gene spanning 17 exons. Homologs have been identified in mouse, rat, zebrafish. Methods of use for the gene, for example in diagnosis and therapy of BBS and in drug screening, also are described.

Abstract: The present invention involves the identification of mutations in various fibulin genes that contribute to age-related macular degeneration (AMD). Compositions and methods are provided to predict, diagnose and treat AMD using fibulin-1, fibulin-2, fibulin-4, fibulin-5 and fibulin-6 as targets.

Abstract: Methods and compositions for treating a congenital heart disease and methods and compositions for prognosing or diagnosing a congenital heart disease in a subject are disclosed.